[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fVC-DLMC8ymh4uE9V8z8tQ0iz49v-5Rp6QNe88I3vujc":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":83,"rows":90},"argenx",[4],79,false,38,31,9106,15,3,[14,17,20,23,25,28,31,33],{"name":15,"count":16},"Generalized Myasthenia Gravis",11,{"name":18,"count":19},"Healthy Volunteers",9,{"name":21,"count":22},"Myasthenia Gravis",6,{"name":24,"count":22},"gMG",{"name":26,"count":27},"Primary Immune Thrombocytopenia",5,{"name":29,"count":30},"CIDP",4,{"name":32,"count":12},"Myositis",{"name":34,"count":12},"Dermatomyositis",[36,41,46,51,56,59,64,68,73,78],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT06298552","A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis","2025-06-30","Efgartigimod IV",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT05907096","ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function","2025-10-16","ARGX-117",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT06558279","A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis","2026-01","Efgartigimod PH20 SC",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT06441682","A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)","2026-08","ARGX-119",{"nctId":57,"briefTitle":58,"date":54,"intervention":50},"NCT06909214","A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT06742190","A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy","2026-09","Empasiprubart",{"nctId":65,"briefTitle":66,"date":67,"intervention":50},"NCT06392386","A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis","2026-09-30",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT04812925","A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia","2026-10-01","efgartigimod PH20 SC",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT06284954","A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis","2026-11","Empasiprubart IV",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT05523167","A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.","2026-12-01","EFG PH20 SC",[84,85,86,87,88,89],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[91,333,456,515,550,572,593,616,666,706,729,752,778,796,820,930,1008,1038,1062,1080,1105,1128,1154,1172,1196,1219,1243,1261],{"intervention":50,"totalTrials":92,"cells":93},23,{"EARLY_PHASE1":94,"PHASE1":97,"PHASE2":111,"PHASE3":137,"PHASE4":293,"NA":313},{"trials":95,"activeCount":96},[],0,{"trials":98,"activeCount":96},[99],{"nctId":100,"briefTitle":101,"status":102,"phases":103,"primaryCompletion":104,"completion":105,"start":106,"enrollment":107,"conditions":108,"interventions":109},"NCT04564066","A Phase 1 Study to Compare the Safety and Effect of Efgartigimod as an Intravenous Infusion With the Effect of Efgartigimod as a Subcutaneous Injection in Healthy Volunteers","COMPLETED",[85],"2020-12-24","2021-02-11","2020-08-18",54,[18],[110,72],"efgartigimod IV",{"trials":112,"activeCount":136,"soonestReadout":118},[113,125],{"nctId":114,"briefTitle":115,"status":116,"phases":117,"primaryCompletion":118,"completion":119,"start":120,"enrollment":121,"conditions":122,"interventions":124},"NCT06655155","A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis","RECRUITING",[86],"2027-02","2027-09","2024-11-11",81,[123],"Systemic Sclerosis (SSc)",[50],{"nctId":126,"briefTitle":127,"status":128,"phases":129,"primaryCompletion":130,"completion":130,"start":131,"enrollment":132,"conditions":133,"interventions":135},"NCT04280718","A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)","ACTIVE_NOT_RECRUITING",[86],"2027-04-30","2020-09-18",229,[134],"Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)",[50],2,{"trials":138,"activeCount":292,"soonestReadout":49},[139,151,162,168,182,190,202,213,219,227,236,248,257,266,273,282],{"nctId":140,"briefTitle":141,"status":142,"phases":143,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":148,"interventions":150},"NCT06307626","A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.","TERMINATED",[87],"2025-12-15","2026-02-12","2024-03-28",105,[149],"Thyroid Eye Disease",[50],{"nctId":152,"briefTitle":153,"status":142,"phases":154,"primaryCompletion":155,"completion":155,"start":156,"enrollment":157,"conditions":158,"interventions":160},"NCT05681481","A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid",[87],"2025-03-20","2023-03-22",64,[159],"Bullous Pemphigoid",[72,161],"Prednisone",{"nctId":65,"briefTitle":66,"status":116,"phases":163,"primaryCompletion":67,"completion":67,"start":164,"enrollment":165,"conditions":166,"interventions":167},[86,87],"2024-06-28",12,[15],[50],{"nctId":169,"briefTitle":170,"status":171,"phases":172,"primaryCompletion":173,"completion":173,"start":174,"enrollment":175,"conditions":176,"interventions":181},"NCT05979441","A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy","ENROLLING_BY_INVITATION",[87],"2028-09","2023-09-12",240,[32,177,34,178,179,180],"Active Idiopathic Inflammatory Myopathy","Polymyositis","Immune-Mediated Necrotizing Myopathy","Antisynthetase Syndrome",[50],{"nctId":183,"briefTitle":184,"status":142,"phases":185,"primaryCompletion":144,"completion":145,"start":186,"enrollment":187,"conditions":188,"interventions":189},"NCT06307613","A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease",[87],"2024-03-27",102,[149],[50],{"nctId":191,"briefTitle":192,"status":193,"phases":194,"primaryCompletion":195,"completion":196,"start":197,"enrollment":198,"conditions":199,"interventions":201},"NCT07596849","A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.","NOT_YET_RECRUITING",[87],"2028-06","2030-05","2026-06",230,[200],"Graves Disease",[72],{"nctId":203,"briefTitle":204,"status":128,"phases":205,"primaryCompletion":206,"completion":207,"start":208,"enrollment":209,"conditions":210,"interventions":212},"NCT06684847","A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome",[87],"2027-07","2028-07","2025-01-15",631,[211],"Primary Sjogrens Disease",[50],{"nctId":69,"briefTitle":70,"status":128,"phases":214,"primaryCompletion":71,"completion":71,"start":215,"enrollment":216,"conditions":217,"interventions":218},[87],"2021-11-17",173,[26],[72],{"nctId":47,"briefTitle":48,"status":128,"phases":220,"primaryCompletion":49,"completion":221,"start":222,"enrollment":223,"conditions":224,"interventions":226},[87],"2027-12","2024-09-18",141,[225],"Myasthenia Gravis, Ocular",[50],{"nctId":228,"briefTitle":229,"status":102,"phases":230,"primaryCompletion":231,"completion":231,"start":232,"enrollment":233,"conditions":234,"interventions":235},"NCT04818671","Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis",[87],"2024-12-31","2021-04-26",184,[15],[72],{"nctId":237,"briefTitle":238,"status":142,"phases":239,"primaryCompletion":240,"completion":240,"start":241,"enrollment":242,"conditions":243,"interventions":246},"NCT04598477","A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)",[87],"2024-03-25","2021-07-15",183,[244,245],"Pemphigus Vulgaris","Pemphigus Foliaceus",[72,247],"prednisone",{"nctId":249,"briefTitle":250,"status":102,"phases":251,"primaryCompletion":252,"completion":252,"start":253,"enrollment":254,"conditions":255,"interventions":256},"NCT04687072","A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia",[87],"2023-10-09","2020-12-16",207,[26],[50],{"nctId":258,"briefTitle":259,"status":102,"phases":260,"primaryCompletion":261,"completion":261,"start":262,"enrollment":263,"conditions":264,"interventions":265},"NCT05267600","A Phase 2\u002F3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid",[86,87],"2024-09-13","2022-06-09",98,[159],[72,161],{"nctId":267,"briefTitle":268,"status":193,"phases":269,"primaryCompletion":195,"completion":196,"start":197,"enrollment":198,"conditions":270,"interventions":272},"NCT07570316","A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease",[87],[271,200],"Graves' Disease",[50],{"nctId":274,"briefTitle":275,"status":102,"phases":276,"primaryCompletion":277,"completion":277,"start":278,"enrollment":279,"conditions":280,"interventions":281},"NCT04598451","A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)",[87],"2023-08-22","2020-12-01",222,[244,245],[72,247],{"nctId":283,"briefTitle":284,"status":102,"phases":285,"primaryCompletion":286,"completion":287,"start":288,"enrollment":289,"conditions":290,"interventions":291},"NCT04735432","Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis",[87],"2021-11-02","2021-12-13","2021-02-05",110,[15],[72,110],7,{"trials":294,"activeCount":312,"soonestReadout":54},[295,304],{"nctId":296,"briefTitle":297,"status":102,"phases":298,"primaryCompletion":299,"completion":299,"start":300,"enrollment":92,"conditions":301,"interventions":303},"NCT06637072","A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC",[88],"2026-02-19","2024-12-10",[302],"Chronic Inflammatory Demyelinating Polyneuropathy",[50],{"nctId":57,"briefTitle":58,"status":116,"phases":305,"primaryCompletion":54,"completion":306,"start":307,"enrollment":308,"conditions":309,"interventions":311},[88],"2027-05","2025-04-17",30,[310],"New Onset Generalized Myasthenia Gravis (gMG)",[50],1,{"trials":314,"activeCount":312,"soonestReadout":319},[315,326],{"nctId":316,"briefTitle":317,"status":116,"phases":318,"primaryCompletion":319,"completion":319,"start":320,"enrollment":321,"conditions":322,"interventions":325},"NCT07264426","Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study",[],"2029-10","2025-08-11",200,[323,29,324],"Chronic Inflammatory Demyelinating Polyradiculoneuropathy","CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)",[50],{"nctId":327,"briefTitle":328,"status":329,"phases":330,"conditions":331,"interventions":332},"NCT04777734","Pre-Approval Access for Efgartigimod PH20 SC in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","AVAILABLE",[],[134,29],[50],{"intervention":40,"totalTrials":165,"cells":334},{"EARLY_PHASE1":335,"PHASE1":337,"PHASE2":353,"PHASE3":388,"PHASE4":446,"NA":448},{"trials":336,"activeCount":96},[],{"trials":338,"activeCount":96},[339,349],{"nctId":340,"briefTitle":341,"status":102,"phases":342,"primaryCompletion":343,"completion":343,"start":344,"enrollment":345,"conditions":346,"interventions":348},"NCT05927415","A Study to Test How Kidney Problems Influence the Blood Concentrations of Efgartigimod",[85],"2024-06-12","2023-07-17",33,[347],"Renal Impairment",[40],{"nctId":100,"briefTitle":101,"status":102,"phases":350,"primaryCompletion":104,"completion":105,"start":106,"enrollment":107,"conditions":351,"interventions":352},[85],[18],[110,72],{"trials":354,"activeCount":312,"soonestReadout":369},[355,365,377],{"nctId":356,"briefTitle":357,"status":142,"phases":358,"primaryCompletion":359,"completion":359,"start":360,"enrollment":361,"conditions":362,"interventions":364},"NCT05810961","A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014)",[86],"2024-08-05","2023-02-20",8,[363],"Membranous Nephropathy",[110],{"nctId":366,"briefTitle":367,"status":116,"phases":368,"primaryCompletion":369,"completion":369,"start":370,"enrollment":371,"conditions":372,"interventions":376},"NCT07284420","ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod",[86],"2028-03-07","2025-12-19",70,[373,21,374,24,15,375],"AChR-Ab Seropositive Generalized Myasthenia Gravis","MG","Generalized Myasthenia Gravis (gMG)",[40,77],{"nctId":378,"briefTitle":379,"status":102,"phases":380,"primaryCompletion":381,"completion":382,"start":383,"enrollment":384,"conditions":385,"interventions":387},"NCT05810948","A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013)",[86],"2025-07-02","2025-09-01","2023-02-21",73,[386],"Lupus Nephritis",[110],{"trials":389,"activeCount":30,"soonestReadout":39},[390,407,418,426,434,442],{"nctId":391,"briefTitle":392,"status":116,"phases":393,"primaryCompletion":394,"completion":395,"start":396,"enrollment":397,"conditions":398,"interventions":406},"NCT07194850","A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)",[86,87],"2028-10","2030-10","2025-10-20",24,[399,400,401,402,403,404,405],"Immune Thrombocytopenia (ITP)","ITP - Immune Thrombocytopenia","ITP","Immune Thrombocytopenic Purpura","Immune Thrombocytopenic Purpura ( ITP )","Idiopathic Thrombocytopenic Purpura","Idiopathic Thrombocytopenic Purpura (ITP)",[40],{"nctId":408,"briefTitle":409,"status":102,"phases":410,"primaryCompletion":411,"completion":412,"start":413,"enrollment":414,"conditions":415,"interventions":417},"NCT04980495","An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis",[87],"2023-08-24","2025-10-06","2021-12-16",69,[15,416,24],"MG - Myasthenia Gravis",[40],{"nctId":37,"briefTitle":38,"status":128,"phases":419,"primaryCompletion":39,"completion":420,"start":421,"enrollment":422,"conditions":423,"interventions":425},[87],"2027-06","2024-04-16",119,[15,24,424,21],"Myasthenia Gravis, Generalized",[40],{"nctId":427,"briefTitle":428,"status":116,"phases":429,"primaryCompletion":195,"completion":195,"start":430,"enrollment":414,"conditions":431,"interventions":433},"NCT06544499","A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia",[87],"2024-10-18",[432],"Primary Immune Thrombocytopenia (ITP)",[40],{"nctId":435,"briefTitle":436,"status":116,"phases":437,"primaryCompletion":438,"completion":438,"start":439,"enrollment":165,"conditions":440,"interventions":441},"NCT04833894","Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis",[86,87],"2027-03","2021-10-26",[15],[40],{"nctId":283,"briefTitle":284,"status":102,"phases":443,"primaryCompletion":286,"completion":287,"start":288,"enrollment":289,"conditions":444,"interventions":445},[87],[15],[72,110],{"trials":447,"activeCount":96},[],{"trials":449,"activeCount":312,"soonestReadout":369},[450],{"nctId":451,"briefTitle":452,"status":116,"phases":453,"primaryCompletion":369,"completion":369,"start":370,"enrollment":371,"conditions":454,"interventions":455},"NCT07294170","ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis",[],[21,374,24,15,375,373],[40,77],{"intervention":77,"totalTrials":22,"cells":457},{"EARLY_PHASE1":458,"PHASE1":460,"PHASE2":484,"PHASE3":495,"PHASE4":507,"NA":509},{"trials":459,"activeCount":96},[],{"trials":461,"activeCount":136,"soonestReadout":438},[462,473],{"nctId":463,"briefTitle":464,"status":193,"phases":465,"primaryCompletion":466,"completion":467,"start":468,"enrollment":469,"conditions":470,"interventions":472},"NCT07610564","A Study to Assess the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults With Multifocal Motor Neuropathy",[85],"2028-02-01","2030-04-01","2026-06-30",60,[471],"Multifocal Motor Neuropathy (MMN)",[77],{"nctId":474,"briefTitle":475,"status":116,"phases":476,"primaryCompletion":438,"completion":477,"start":478,"enrollment":479,"conditions":480,"interventions":481},"NCT07612020","A Study to Assess the Absolute Bioavailability of Empasiprubart SC Administered With an Autoinjector and the Pharmacokinetic Noninferiority of Empasiprubart SC Versus Intravenous (IV) in Healthy Adult Participants",[85],"2027-10","2026-03-16",130,[18],[482,483],"empasiprubart SC AI","empasiprubart IV",{"trials":485,"activeCount":136,"soonestReadout":76},[486,491],{"nctId":74,"briefTitle":75,"status":128,"phases":487,"primaryCompletion":76,"completion":76,"start":488,"enrollment":12,"conditions":489,"interventions":490},[86],"2024-08-20",[34,32],[77],{"nctId":366,"briefTitle":367,"status":116,"phases":492,"primaryCompletion":369,"completion":369,"start":370,"enrollment":371,"conditions":493,"interventions":494},[86],[373,21,374,24,15,375],[40,77],{"trials":496,"activeCount":312,"soonestReadout":501},[497],{"nctId":498,"briefTitle":499,"status":116,"phases":500,"primaryCompletion":501,"completion":502,"start":503,"enrollment":504,"conditions":505,"interventions":506},"NCT07091630","A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP",[87],"2027-10-07","2031-01-23","2025-09-16",160,[302,29,323],[77],{"trials":508,"activeCount":96},[],{"trials":510,"activeCount":312,"soonestReadout":369},[511],{"nctId":451,"briefTitle":452,"status":116,"phases":512,"primaryCompletion":369,"completion":369,"start":370,"enrollment":371,"conditions":513,"interventions":514},[],[21,374,24,15,375,373],[40,77],{"intervention":63,"totalTrials":136,"cells":516},{"EARLY_PHASE1":517,"PHASE1":519,"PHASE2":521,"PHASE3":523,"PHASE4":546,"NA":548},{"trials":518,"activeCount":96},[],{"trials":520,"activeCount":96},[],{"trials":522,"activeCount":96},[],{"trials":524,"activeCount":136,"soonestReadout":62},[525,534],{"nctId":60,"briefTitle":61,"status":128,"phases":526,"primaryCompletion":62,"completion":527,"start":528,"enrollment":529,"conditions":530,"interventions":532},[87],"2029-12","2024-12-18",154,[471,531],"MMN",[63,533],"IVIG",{"nctId":535,"briefTitle":536,"status":116,"phases":537,"primaryCompletion":119,"completion":538,"start":539,"enrollment":540,"conditions":541,"interventions":543},"NCT06920004","A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP",[87],"2030-09","2025-08-22",218,[302,29,542],"CIDP - Chronic Inflammatory Demyelinating Polyneuropathy",[544,545],"empasiprubart","IVIg",{"trials":547,"activeCount":96},[],{"trials":549,"activeCount":96},[],{"intervention":533,"totalTrials":136,"cells":551},{"EARLY_PHASE1":552,"PHASE1":554,"PHASE2":556,"PHASE3":558,"PHASE4":568,"NA":570},{"trials":553,"activeCount":96},[],{"trials":555,"activeCount":96},[],{"trials":557,"activeCount":96},[],{"trials":559,"activeCount":136,"soonestReadout":62},[560,564],{"nctId":60,"briefTitle":61,"status":128,"phases":561,"primaryCompletion":62,"completion":527,"start":528,"enrollment":529,"conditions":562,"interventions":563},[87],[471,531],[63,533],{"nctId":535,"briefTitle":536,"status":116,"phases":565,"primaryCompletion":119,"completion":538,"start":539,"enrollment":540,"conditions":566,"interventions":567},[87],[302,29,542],[544,545],{"trials":569,"activeCount":96},[],{"trials":571,"activeCount":96},[],{"intervention":82,"totalTrials":312,"cells":573},{"EARLY_PHASE1":574,"PHASE1":576,"PHASE2":578,"PHASE3":580,"PHASE4":589,"NA":591},{"trials":575,"activeCount":96},[],{"trials":577,"activeCount":96},[],{"trials":579,"activeCount":96},[],{"trials":581,"activeCount":312,"soonestReadout":81},[582],{"nctId":79,"briefTitle":80,"status":128,"phases":583,"primaryCompletion":81,"completion":584,"start":585,"enrollment":586,"conditions":587,"interventions":588},[86,87],"2027-02-01","2022-10-12",265,[177,32,34,178,179,180],[82],{"trials":590,"activeCount":96},[],{"trials":592,"activeCount":96},[],{"intervention":594,"totalTrials":312,"cells":595},"Efgartigimod IV or Efgartigimod PH20 SC",{"EARLY_PHASE1":596,"PHASE1":598,"PHASE2":600,"PHASE3":602,"PHASE4":612,"NA":614},{"trials":597,"activeCount":96},[],{"trials":599,"activeCount":96},[],{"trials":601,"activeCount":96},[],{"trials":603,"activeCount":312,"soonestReadout":608},[604],{"nctId":605,"briefTitle":606,"status":171,"phases":607,"primaryCompletion":608,"completion":608,"start":609,"enrollment":165,"conditions":610,"interventions":611},"NCT05374590","Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis",[86,87],"2029-09","2022-08-18",[15,24],[594],{"trials":613,"activeCount":96},[],{"trials":615,"activeCount":96},[],{"intervention":45,"totalTrials":30,"cells":617},{"EARLY_PHASE1":618,"PHASE1":620,"PHASE2":632,"PHASE3":660,"PHASE4":662,"NA":664},{"trials":619,"activeCount":96},[],{"trials":621,"activeCount":96},[622],{"nctId":623,"briefTitle":624,"status":102,"phases":625,"primaryCompletion":626,"completion":626,"start":627,"enrollment":289,"conditions":628,"interventions":629},"NCT04532125","SAD and MAD Study With IV and SC Doses of ARGX-117",[85],"2022-08-26","2020-08-03",[18],[45,630,631],"ARGX-117 + rHuPH20","ARGX-117 PH20 SC",{"trials":633,"activeCount":136,"soonestReadout":44},[634,642,651],{"nctId":42,"briefTitle":43,"status":128,"phases":635,"primaryCompletion":44,"completion":636,"start":637,"enrollment":638,"conditions":639,"interventions":641},[86],"2026-07-31","2024-02-17",103,[640],"Delayed Graft Function",[45],{"nctId":643,"briefTitle":644,"status":128,"phases":645,"primaryCompletion":646,"completion":646,"start":647,"enrollment":648,"conditions":649,"interventions":650},"NCT05405361","A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy",[86],"2029-09-30","2023-01-18",51,[471],[45],{"nctId":652,"briefTitle":653,"status":102,"phases":654,"primaryCompletion":655,"completion":655,"start":656,"enrollment":107,"conditions":657,"interventions":659},"NCT05225675","A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifocal Motor Neuropathy",[86],"2024-06-04","2022-03-31",[658],"Multifocal Motor Neuropathy",[45],{"trials":661,"activeCount":96},[],{"trials":663,"activeCount":96},[],{"trials":665,"activeCount":96},[],{"intervention":55,"totalTrials":12,"cells":667},{"EARLY_PHASE1":668,"PHASE1":670,"PHASE2":692,"PHASE3":700,"PHASE4":702,"NA":704},{"trials":669,"activeCount":96},[],{"trials":671,"activeCount":312,"soonestReadout":676},[672,684],{"nctId":673,"briefTitle":674,"status":116,"phases":675,"primaryCompletion":676,"completion":677,"start":678,"enrollment":679,"conditions":680,"interventions":683},"NCT06436742","A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)",[85],"2027-08-24","2028-01-24","2024-09-24",16,[681,682],"Congenital Myasthenic Syndrome","CMS",[55],{"nctId":685,"briefTitle":686,"status":102,"phases":687,"primaryCompletion":688,"completion":688,"start":383,"enrollment":689,"conditions":690,"interventions":691},"NCT05670704","A Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of ARGX-119 in Healthy Participants",[85],"2024-08-08",112,[18],[55],{"trials":693,"activeCount":312,"soonestReadout":54},[694],{"nctId":52,"briefTitle":53,"status":128,"phases":695,"primaryCompletion":54,"completion":54,"start":696,"enrollment":469,"conditions":697,"interventions":699},[86],"2024-10-23",[698],"Amyotrophic Lateral Sclerosis",[55],{"trials":701,"activeCount":96},[],{"trials":703,"activeCount":96},[],{"trials":705,"activeCount":96},[],{"intervention":707,"totalTrials":312,"cells":708},"ARGX-119 IV",{"EARLY_PHASE1":709,"PHASE1":711,"PHASE2":713,"PHASE3":723,"PHASE4":725,"NA":727},{"trials":710,"activeCount":96},[],{"trials":712,"activeCount":96},[],{"trials":714,"activeCount":312,"soonestReadout":719},[715],{"nctId":716,"briefTitle":717,"status":116,"phases":718,"primaryCompletion":719,"completion":719,"start":370,"enrollment":469,"conditions":720,"interventions":722},"NCT07287982","A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy",[86],"2029-05-28",[721],"Spinal Muscular Atrophy (SMA)",[707],{"trials":724,"activeCount":96},[],{"trials":726,"activeCount":96},[],{"trials":728,"activeCount":96},[],{"intervention":730,"totalTrials":312,"cells":731},"Efgartigimod PH20 SC - prefilled syringe",{"EARLY_PHASE1":732,"PHASE1":734,"PHASE2":736,"PHASE3":746,"PHASE4":748,"NA":750},{"trials":733,"activeCount":96},[],{"trials":735,"activeCount":96},[],{"trials":737,"activeCount":312,"soonestReadout":119},[738],{"nctId":739,"briefTitle":740,"status":116,"phases":741,"primaryCompletion":119,"completion":119,"start":742,"enrollment":308,"conditions":743,"interventions":745},"NCT06503731","A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)",[86],"2024-08-30",[744],"Antibody-mediated Rejection",[730],{"trials":747,"activeCount":96},[],{"trials":749,"activeCount":96},[],{"trials":751,"activeCount":96},[],{"intervention":753,"totalTrials":312,"cells":754},"Efgartigimod PH20 (ARGX-113) SC",{"EARLY_PHASE1":755,"PHASE1":757,"PHASE2":759,"PHASE3":772,"PHASE4":774,"NA":776},{"trials":756,"activeCount":96},[],{"trials":758,"activeCount":96},[],{"trials":760,"activeCount":312,"soonestReadout":765},[761],{"nctId":762,"briefTitle":763,"status":193,"phases":764,"primaryCompletion":765,"completion":766,"start":767,"enrollment":768,"conditions":769,"interventions":771},"NCT07583641","A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and Adults",[86],"2030-12-04","2031-07-26","2026-07-13",170,[770],"Autoimmune Encephalitis (AE)",[753],{"trials":773,"activeCount":96},[],{"trials":775,"activeCount":96},[],{"trials":777,"activeCount":96},[],{"intervention":482,"totalTrials":312,"cells":779},{"EARLY_PHASE1":780,"PHASE1":782,"PHASE2":788,"PHASE3":790,"PHASE4":792,"NA":794},{"trials":781,"activeCount":96},[],{"trials":783,"activeCount":312,"soonestReadout":438},[784],{"nctId":474,"briefTitle":475,"status":116,"phases":785,"primaryCompletion":438,"completion":477,"start":478,"enrollment":479,"conditions":786,"interventions":787},[85],[18],[482,483],{"trials":789,"activeCount":96},[],{"trials":791,"activeCount":96},[],{"trials":793,"activeCount":96},[],{"trials":795,"activeCount":96},[],{"intervention":797,"totalTrials":312,"cells":798},"ARGX-124",{"EARLY_PHASE1":799,"PHASE1":801,"PHASE2":812,"PHASE3":814,"PHASE4":816,"NA":818},{"trials":800,"activeCount":96},[],{"trials":802,"activeCount":312,"soonestReadout":807},[803],{"nctId":804,"briefTitle":805,"status":116,"phases":806,"primaryCompletion":807,"completion":807,"start":808,"enrollment":809,"conditions":810,"interventions":811},"NCT07377396","A Study to Assess the Safety of ARGX-124 in Healthy Volunteers",[85],"2026-12-31","2026-01-26",104,[18],[797],{"trials":813,"activeCount":96},[],{"trials":815,"activeCount":96},[],{"trials":817,"activeCount":96},[],{"trials":819,"activeCount":96},[],{"intervention":821,"totalTrials":822,"cells":823},"Efgartigimod",10,{"EARLY_PHASE1":824,"PHASE1":826,"PHASE2":837,"PHASE3":877,"PHASE4":907,"NA":909},{"trials":825,"activeCount":96},[],{"trials":827,"activeCount":96},[828],{"nctId":829,"briefTitle":830,"status":102,"phases":831,"primaryCompletion":832,"completion":832,"start":215,"enrollment":833,"conditions":834,"interventions":835},"NCT05163834","Immune Response to PNEUMOVAX 23 in Healthy Adults Receiving Efgartigimod IV",[85],"2022-03-08",36,[18],[821,836],"PNEUMOVAX 23",{"trials":838,"activeCount":96},[839,848,858,868],{"nctId":840,"briefTitle":841,"status":102,"phases":842,"primaryCompletion":843,"completion":843,"start":844,"enrollment":397,"conditions":845,"interventions":847},"NCT06203457","Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome",[86],"2025-02-03","2023-11-29",[846],"Primary Sjögren's Syndrome",[821],{"nctId":849,"briefTitle":850,"status":102,"phases":851,"primaryCompletion":852,"completion":852,"start":853,"enrollment":854,"conditions":855,"interventions":857},"NCT05633407","Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS",[86],"2024-04-18","2022-09-23",53,[856],"Postural Orthostatic Tachycardia Syndrome",[821],{"nctId":859,"briefTitle":860,"status":102,"phases":861,"primaryCompletion":862,"completion":863,"start":864,"enrollment":865,"conditions":866,"interventions":867},"NCT05817669","A Study of the Safety and Effectiveness of Efgartigimod in Patients With Primary Sjögren's Syndrome (pSS)",[86],"2024-01-29","2024-02-12","2023-04-04",34,[846],[821],{"nctId":869,"briefTitle":870,"status":142,"phases":871,"primaryCompletion":872,"completion":872,"start":873,"enrollment":345,"conditions":874,"interventions":876},"NCT05918978","Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS",[86],"2024-08-15","2023-06-20",[875],"Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome",[821],{"trials":878,"activeCount":96},[879,889,898],{"nctId":880,"briefTitle":881,"status":102,"phases":882,"primaryCompletion":883,"completion":883,"start":884,"enrollment":885,"conditions":886,"interventions":887},"NCT04188379","A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).",[87],"2022-02-03","2019-12-16",131,[26],[888],"efgartigimod",{"nctId":890,"briefTitle":891,"status":892,"phases":893,"primaryCompletion":894,"completion":894,"start":895,"enrollment":96,"conditions":896,"interventions":897},"NCT04274452","A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP)","WITHDRAWN",[87],"2021-09-01","2020-06-29",[432],[888],{"nctId":899,"briefTitle":900,"status":102,"phases":901,"primaryCompletion":902,"completion":902,"start":903,"enrollment":904,"conditions":905,"interventions":906},"NCT04225156","A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).",[87],"2026-03-11","2020-06-02",101,[26],[888],{"trials":908,"activeCount":96},[],{"trials":910,"activeCount":136,"soonestReadout":924},[911,920],{"nctId":912,"briefTitle":913,"status":116,"phases":914,"primaryCompletion":915,"completion":915,"start":916,"enrollment":917,"conditions":918,"interventions":919},"NCT06298565","A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa",[],"2034-06","2024-11-04",680,[21],[888],{"nctId":921,"briefTitle":922,"status":116,"phases":923,"primaryCompletion":924,"completion":925,"start":926,"enrollment":927,"conditions":928,"interventions":929},"NCT06299748","A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and\u002For Breastfeeding.",[],"2033-01","2033-12","2023-11-30",279,[21,542],[821],{"intervention":931,"totalTrials":292,"cells":932},"ARGX-113",{"EARLY_PHASE1":933,"PHASE1":935,"PHASE2":957,"PHASE3":983,"PHASE4":1004,"NA":1006},{"trials":934,"activeCount":96},[],{"trials":936,"activeCount":96},[937,947],{"nctId":938,"briefTitle":939,"status":102,"phases":940,"primaryCompletion":941,"completion":942,"start":943,"enrollment":944,"conditions":945,"interventions":946},"NCT03457649","IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers",[85],"2016-11-15","2017-02-21","2015-09-09",62,[18],[931],{"nctId":948,"briefTitle":949,"status":102,"phases":950,"primaryCompletion":951,"completion":951,"start":952,"enrollment":953,"conditions":954,"interventions":956},"NCT03334084","A Study to Compare the PK, PD and Safety and Tolerability of a SC With an IV Formulation of ARGX-113 in Healthy Male Subjects",[85],"2018-09-19","2017-10-11",40,[955],"Bioavailability Study",[931],{"trials":958,"activeCount":96},[959,967,975],{"nctId":960,"briefTitle":961,"status":102,"phases":962,"primaryCompletion":963,"completion":963,"start":964,"enrollment":865,"conditions":965,"interventions":966},"NCT03334058","A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus",[86],"2020-10-28","2017-10-18",[244,245],[931],{"nctId":968,"briefTitle":969,"status":102,"phases":970,"primaryCompletion":971,"completion":971,"start":972,"enrollment":397,"conditions":973,"interventions":974},"NCT02965573","A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness",[86],"2017-10-20","2016-12-30",[21],[931],{"nctId":976,"briefTitle":977,"status":102,"phases":978,"primaryCompletion":979,"completion":979,"start":980,"enrollment":8,"conditions":981,"interventions":982},"NCT03102593","A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP",[86],"2019-04-09","2017-03-13",[26],[931],{"trials":984,"activeCount":96},[985,994],{"nctId":986,"briefTitle":987,"status":102,"phases":988,"primaryCompletion":989,"completion":989,"start":990,"enrollment":991,"conditions":992,"interventions":993},"NCT03669588","An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness",[87],"2020-04-06","2018-08-22",167,[15],[931],{"nctId":995,"briefTitle":996,"status":102,"phases":997,"primaryCompletion":998,"completion":999,"start":1000,"enrollment":1001,"conditions":1002,"interventions":1003},"NCT03770403","A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness.",[87],"2022-06-23","2022-06-30","2019-03-01",151,[15],[931],{"trials":1005,"activeCount":96},[],{"trials":1007,"activeCount":96},[],{"intervention":161,"totalTrials":30,"cells":1009},{"EARLY_PHASE1":1010,"PHASE1":1012,"PHASE2":1014,"PHASE3":1016,"PHASE4":1034,"NA":1036},{"trials":1011,"activeCount":96},[],{"trials":1013,"activeCount":96},[],{"trials":1015,"activeCount":96},[],{"trials":1017,"activeCount":96},[1018,1022,1026,1030],{"nctId":152,"briefTitle":153,"status":142,"phases":1019,"primaryCompletion":155,"completion":155,"start":156,"enrollment":157,"conditions":1020,"interventions":1021},[87],[159],[72,161],{"nctId":237,"briefTitle":238,"status":142,"phases":1023,"primaryCompletion":240,"completion":240,"start":241,"enrollment":242,"conditions":1024,"interventions":1025},[87],[244,245],[72,247],{"nctId":258,"briefTitle":259,"status":102,"phases":1027,"primaryCompletion":261,"completion":261,"start":262,"enrollment":263,"conditions":1028,"interventions":1029},[86,87],[159],[72,161],{"nctId":274,"briefTitle":275,"status":102,"phases":1031,"primaryCompletion":277,"completion":277,"start":278,"enrollment":279,"conditions":1032,"interventions":1033},[87],[244,245],[72,247],{"trials":1035,"activeCount":96},[],{"trials":1037,"activeCount":96},[],{"intervention":1039,"totalTrials":312,"cells":1040},"efgartigimod PH20 SC in stage B",{"EARLY_PHASE1":1041,"PHASE1":1043,"PHASE2":1045,"PHASE3":1056,"PHASE4":1058,"NA":1060},{"trials":1042,"activeCount":96},[],{"trials":1044,"activeCount":96},[],{"trials":1046,"activeCount":96},[1047],{"nctId":1048,"briefTitle":1049,"status":102,"phases":1050,"primaryCompletion":1051,"completion":1051,"start":1052,"enrollment":1053,"conditions":1054,"interventions":1055},"NCT04281472","A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)",[86],"2023-05-11","2020-04-15",322,[134],[1039],{"trials":1057,"activeCount":96},[],{"trials":1059,"activeCount":96},[],{"trials":1061,"activeCount":96},[],{"intervention":836,"totalTrials":312,"cells":1063},{"EARLY_PHASE1":1064,"PHASE1":1066,"PHASE2":1072,"PHASE3":1074,"PHASE4":1076,"NA":1078},{"trials":1065,"activeCount":96},[],{"trials":1067,"activeCount":96},[1068],{"nctId":829,"briefTitle":830,"status":102,"phases":1069,"primaryCompletion":832,"completion":832,"start":215,"enrollment":833,"conditions":1070,"interventions":1071},[85],[18],[821,836],{"trials":1073,"activeCount":96},[],{"trials":1075,"activeCount":96},[],{"trials":1077,"activeCount":96},[],{"trials":1079,"activeCount":96},[],{"intervention":1081,"totalTrials":312,"cells":1082},"ARGX-110",{"EARLY_PHASE1":1083,"PHASE1":1085,"PHASE2":1097,"PHASE3":1099,"PHASE4":1101,"NA":1103},{"trials":1084,"activeCount":96},[],{"trials":1086,"activeCount":96},[1087],{"nctId":1088,"briefTitle":1089,"status":102,"phases":1090,"primaryCompletion":1091,"completion":1092,"start":1093,"enrollment":16,"conditions":1094,"interventions":1096},"NCT02759250","A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)",[85],"2018-04-25","2018-06","2015-02",[1095],"Cancer",[1081],{"trials":1098,"activeCount":96},[],{"trials":1100,"activeCount":96},[],{"trials":1102,"activeCount":96},[],{"trials":1104,"activeCount":96},[],{"intervention":1106,"totalTrials":312,"cells":1107},"ARGX-111",{"EARLY_PHASE1":1108,"PHASE1":1110,"PHASE2":1120,"PHASE3":1122,"PHASE4":1124,"NA":1126},{"trials":1109,"activeCount":96},[],{"trials":1111,"activeCount":96},[1112],{"nctId":1113,"briefTitle":1114,"status":102,"phases":1115,"primaryCompletion":1116,"completion":1116,"start":1117,"enrollment":397,"conditions":1118,"interventions":1119},"NCT02055066","A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer.",[85],"2017-03","2014-01",[1095],[1106],{"trials":1121,"activeCount":96},[],{"trials":1123,"activeCount":96},[],{"trials":1125,"activeCount":96},[],{"trials":1127,"activeCount":96},[],{"intervention":1129,"totalTrials":312,"cells":1130},"efgartigimod PH20 SC as a prefilled syringe presentation",{"EARLY_PHASE1":1131,"PHASE1":1133,"PHASE2":1146,"PHASE3":1148,"PHASE4":1150,"NA":1152},{"trials":1132,"activeCount":96},[],{"trials":1134,"activeCount":96},[1135],{"nctId":1136,"briefTitle":1137,"status":102,"phases":1138,"primaryCompletion":1139,"completion":1139,"start":1140,"enrollment":1141,"conditions":1142,"interventions":1144},"NCT05817435","A Phase 1 Bioequivalence Study of Efgartigimod PH20 SC Administered Via a Prefilled Syringe Versus a Vial+Syringe Presentation in Healthy Adults",[85],"2023-05-12","2023-03-13",120,[1143],"Bioequivalence",[1129,1145],"efgartigimod PH20 SC as a vial + syringe presentation",{"trials":1147,"activeCount":96},[],{"trials":1149,"activeCount":96},[],{"trials":1151,"activeCount":96},[],{"trials":1153,"activeCount":96},[],{"intervention":1145,"totalTrials":312,"cells":1155},{"EARLY_PHASE1":1156,"PHASE1":1158,"PHASE2":1164,"PHASE3":1166,"PHASE4":1168,"NA":1170},{"trials":1157,"activeCount":96},[],{"trials":1159,"activeCount":96},[1160],{"nctId":1136,"briefTitle":1137,"status":102,"phases":1161,"primaryCompletion":1139,"completion":1139,"start":1140,"enrollment":1141,"conditions":1162,"interventions":1163},[85],[1143],[1129,1145],{"trials":1165,"activeCount":96},[],{"trials":1167,"activeCount":96},[],{"trials":1169,"activeCount":96},[],{"trials":1171,"activeCount":96},[],{"intervention":1173,"totalTrials":312,"cells":1174},"ARGX-213",{"EARLY_PHASE1":1175,"PHASE1":1177,"PHASE2":1188,"PHASE3":1190,"PHASE4":1192,"NA":1194},{"trials":1176,"activeCount":96},[],{"trials":1178,"activeCount":96},[1179],{"nctId":1180,"briefTitle":1181,"status":102,"phases":1182,"primaryCompletion":1183,"completion":1183,"start":1184,"enrollment":1185,"conditions":1186,"interventions":1187},"NCT06968338","A Study to Assess the Safety of ARGX-213 in Healthy Volunteers",[85],"2026-03-20","2025-04-11",88,[18],[1173],{"trials":1189,"activeCount":96},[],{"trials":1191,"activeCount":96},[],{"trials":1193,"activeCount":96},[],{"trials":1195,"activeCount":96},[],{"intervention":1197,"totalTrials":312,"cells":1198},"ARGX-113 with rHuPH20",{"EARLY_PHASE1":1199,"PHASE1":1201,"PHASE2":1211,"PHASE3":1213,"PHASE4":1215,"NA":1217},{"trials":1200,"activeCount":96},[],{"trials":1202,"activeCount":96},[1203],{"nctId":1204,"briefTitle":1205,"status":102,"phases":1206,"primaryCompletion":1207,"completion":1207,"start":1208,"enrollment":345,"conditions":1209,"interventions":1210},"NCT04073589","Efgartigimod Co-administered Subcutaneously With rHuPH20 in Healthy Subjects",[85],"2019-09-26","2019-07-17",[18],[1197],{"trials":1212,"activeCount":96},[],{"trials":1214,"activeCount":96},[],{"trials":1216,"activeCount":96},[],{"trials":1218,"activeCount":96},[],{"intervention":1220,"totalTrials":312,"cells":1221},"ARGX-109",{"EARLY_PHASE1":1222,"PHASE1":1224,"PHASE2":1235,"PHASE3":1237,"PHASE4":1239,"NA":1241},{"trials":1223,"activeCount":96},[],{"trials":1225,"activeCount":96},[1226],{"nctId":1227,"briefTitle":1228,"status":102,"phases":1229,"primaryCompletion":1230,"completion":1230,"start":1231,"enrollment":953,"conditions":1232,"interventions":1234},"NCT06799416","A Study to Assess the Safety of ARGX-109 in Healthy Volunteers",[85],"2025-08-08","2025-01-14",[1233],"Healthy Volunteer",[1220],{"trials":1236,"activeCount":96},[],{"trials":1238,"activeCount":96},[],{"trials":1240,"activeCount":96},[],{"trials":1242,"activeCount":96},[],{"intervention":630,"totalTrials":312,"cells":1244},{"EARLY_PHASE1":1245,"PHASE1":1247,"PHASE2":1253,"PHASE3":1255,"PHASE4":1257,"NA":1259},{"trials":1246,"activeCount":96},[],{"trials":1248,"activeCount":96},[1249],{"nctId":623,"briefTitle":624,"status":102,"phases":1250,"primaryCompletion":626,"completion":626,"start":627,"enrollment":289,"conditions":1251,"interventions":1252},[85],[18],[45,630,631],{"trials":1254,"activeCount":96},[],{"trials":1256,"activeCount":96},[],{"trials":1258,"activeCount":96},[],{"trials":1260,"activeCount":96},[],{"intervention":631,"totalTrials":312,"cells":1262},{"EARLY_PHASE1":1263,"PHASE1":1265,"PHASE2":1271,"PHASE3":1273,"PHASE4":1275,"NA":1277},{"trials":1264,"activeCount":96},[],{"trials":1266,"activeCount":96},[1267],{"nctId":623,"briefTitle":624,"status":102,"phases":1268,"primaryCompletion":626,"completion":626,"start":627,"enrollment":289,"conditions":1269,"interventions":1270},[85],[18],[45,630,631],{"trials":1272,"activeCount":96},[],{"trials":1274,"activeCount":96},[],{"trials":1276,"activeCount":96},[],{"trials":1278,"activeCount":96},[]]